Prima and Neopharm enter into licence for CVac in Israel

0.0250 (0.00%)View full PRR report with
  1. 42.0k
    Posts

    PRR - Prima and Neopharm enter into licence for CVac in Israel

    Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) (Prima, the Company) is pleased to announce that it has entered into a binding term sheet granting Neopharm Group (Neopharm) an exclusive license (License) to market and sell CVac, a personalized immunocellular therapeutic under investigation for the treatment of epithelial ovarian cancer, in Israel and the Palestinian Authority. Prima and Neopharm will execute a final agreement within ninety (90) days.

Your browser is too old for TopStocks and not secure. Please update your browser